Skip to main content
. Author manuscript; available in PMC: 2021 Feb 1.
Published in final edited form as: Eur J Cancer. 2020 Jan 8;126:78–90. doi: 10.1016/j.ejca.2019.12.006

Figure 4. Landmark analysis of PFS24 based on radiographic imaging at time of treatment in patients treated with R-chemotherapy.

Figure 4.

Kaplan-Meier plots of overall survival (OS) since 2 years landmark stratified by PFS24 status in patients with stage II-IV disease treated with rituximab plus chemotherapy (R-Chemo). (A) MSKCC cohort. (B) FOLL05 cohort. When comparing OS by PFS24 status, PFS24 failures staged by CT had a worse outcome than those who were staged with PET. For CT-staged patients who failed PFS24, the estimated 10-year OS rate was 44% versus PET-staged that was 67%. The results were reproduced in the validation cohort where CT-imaged PFS24 failures had a an estimated 5-year OS rate of 67% versus PET-imaged PFS24 failures had an estimated 5-year OS rate of 84%.